The outbreak of COVID-19 has created a landslide of publications, from different sources and unequal impact. We considered that the first 3 months are crucial to understand how knowledge has been generated by performing a bibliometric analysis, including the citations to these articles to guide researchers in exploring this field, and to evaluate the relationship between confirmed COVID-19 cases and deaths with the number of papers per country. Scientific publications were obtained from PubMed (January-March 2020) and their citations during the first 6 months retrieved from the Scopus database. An analysis of the number of papers by country, approach (type and category of publication), and impact was made. A multiple linear regression model was implemented to analyze the correlation between the number of publications and confirmed cases and deaths. A total of 2,530 publications were analyzed with 59,104 citations (23.4 citations/article), written by authors from 67 countries. China was the country with more publications (988, 39%) and more citations (36,416, 63%) followed by the United States with 423 articles (16.7%) and 7,458 citations (12.6%). The coauthorship network identified 10,756 authors. According to the multivariate analysis, both confirmed cases and deaths were significantly correlated with the number of publications per country (corrected by population size and gross domestic product). The correlation with the number of publications suggests that cases and deaths had some impact on the medical literature, reflecting how rapidly the scientific community has been on the frontline in the fight against COVID-19.
Despite its beneficial effects for the cardiovascular system, taurine remains a controversial substance. Taurine increases cardiac muscle strength and prevents arrhythmias, but its benefits go beyond this. Determining taurine levels may become an issue of life or death. In aneurysmal subarachnoid hemorrhage, taurine may be a warning signal informing of the risk of death in a patient. High plasma taurine levels may identify those patients at a high risk for death or a vegetative state at discharge from the hospital; thus, taurine may be a vital marker for the prognosis of this disorder. This is even more relevant considering that the result occurred in patients with a good neurological grade at admission that would usually receive a good prognosis but, despite this, one out of four died or remained in a vegetative state. Maybe taurine is key to explain this apparent paradox.
Background: Coronavirus disease 2019 (COVID19) is a novel pandemic disease caused by the β-coronavirus SARS-CoV-2. This disease affects primarily the respiratory organs, but the vascular system may also be compromised. COVID19 may lead to either coagulopathies or hemorrhagic disorders involving the central nervous system. Risk factors for a fatal outcome have been suggested but not completely elucidated. Objectives: This systematic review protocol aims to identify clinical, imaging and laboratory variables associated with intra-hospital mortality in patients with COVID19 and cerebrovascular disease. Materials and Methods: Studies will be retrieved from Web of Science, MEDLINE, Scopus, EBSCOhost, Ovid, Rayyan’s COVID-19 Open Research Dataset, and Google Scholar. Inclusion criteria will be observational studies or clinical trials describing patients with both COVID19 and cerebrovascular disease. Exclusion criteria will be studies whose patients remained hospitalized with no defined outcome (intrahospital mortality or discharge), studies written in languages different than English, published before 2019 or whose full-texts could not be retrieved. All demographic, laboratory and imaging variables will be extracted. Data synthesis will be presented in graphs, figures, and summary of findings tables. A global mortality rate will be calculated. A narrative synthesis will be included. A meta-analysis will be performed. For mortality rate and statistical synthesis, only studies reporting the main outcome (intra-hospital mortality or discharge) will be considered. Quality of the evidence will be assessed with the JBI Critical Appraisal tools. This protocol received no funding and isregistered in PROSPERO.